Skip to content
Home/Companies/Healthcare/OnKure Therapeutics
OnKure Therapeutics

OnKure Therapeutics

Healthcare·US·Exited 2024·Held 1yr
Entry
2023
Hold
1yr
Exit
2024

Who owns OnKure Therapeutics?

OnKure Therapeutics was owned by Abingworth through Abingworth Bioventures 8 (2021 vintage) from 2023 to 2024, exited via IPO.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQUS
SectorHealthcare
StatusActive
Websiteonkuretherapeutics.com
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2024

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Myricx Bio
Exited 2026
BiotechUK· 2024
to

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track OnKure Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on OnKure Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue